论文部分内容阅读
目的探讨依达拉奉联合奥扎格雷治疗缺血性脑卒中患者的临床疗效。方法选取2014年1月至2015年6月辽宁省营口市老边区人民医院收治的82例缺血性脑卒中患者为研究对象,采用随机数字表法将其分为观察组与对照组,各41例。对照组患者给予奥扎格雷,观察组患者在对照组基础上采用依达拉奉进行治疗,比较两组患者的临床治疗效果、神经功能缺损程度及日常生活能力。结果经治疗后,观察组患者的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的美国国立卫生研究院卒中量表(NIHSS)评分明显低于对照组,日常生活能力量表(ADL)评分明显高于对照组,差异均有统计学意义(均P<0.05)。结论依达拉奉联合奥扎格雷治疗缺血性脑卒中患者临床疗效显著,不仅能改善患者脑神经缺损程度,还能提高其日常生活能力。
Objective To investigate the clinical efficacy of edaravone and ozagrel in the treatment of patients with ischemic stroke. Methods A total of 82 ischemic stroke patients admitted to the People’s Hospital of Laobian District, Yingkou City, Liaoning Province from January 2014 to June 2015 were selected as study subjects. The patients were divided into observation group and control group by random number table example. The patients in the control group were given ozagrel and the patients in the observation group were treated with edaravone on the basis of the control group. The clinical effects, the degree of neurological deficits and their daily living ability were compared between the two groups. Results After treatment, the total effective rate in the observation group was significantly higher than that in the control group (P <0.05). After treatment, the NIHSS score in the observation group was significantly lower In the control group, ADL score was significantly higher than that of the control group, the difference was statistically significant (P <0.05). Conclusion Edaravone combined with ozagrel in the treatment of ischemic stroke patients with significant clinical efficacy, not only can improve the degree of patients with cerebral nerve defects, but also improve their daily living ability.